Evaluation of Local and Systemic Reactogenicity Following Serial Administration of ADVAX, a Clade C DNA Vaccine, ADVAX e/g + ADVAX p/n-t, by Ichor TriGrid in Vivo Electroporation to HIV-Uninfected, Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 07 May 2011
At a glance
- Drugs ADVAX (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms ADVAX-EP
- 07 May 2011 NCT reports actual end date is Apr 2011.
- 01 Dec 2009 Positive results presented at the AIDS Vaccine Conference. Additional analyses are underway.
- 01 Dec 2009 Status changed from active, no longer recruiting to completed.